CADL vs. BCAX

Last updated Apr 1, 2026

Compare and contrast key facts about Candel Therapeutics, Inc. (CADL) and Bicara Therapeutics Inc (BCAX).

Performance

CADL vs. BCAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Candel Therapeutics, Inc. (CADL) and Bicara Therapeutics Inc (BCAX). The values are adjusted to include any dividend payments, if applicable.

CADL vs. BCAX - Yearly Performance Comparison

	2026 (YTD)	2025	2024
CADL Candel Therapeutics, Inc.	-13.27%	-34.91%	23.82%
BCAX Bicara Therapeutics Inc	18.18%	-3.39%	-25.59%

Fundamentals

Market Cap CADL : $269.00M BCAX : $1.10B
EPS CADL : -$0.16 BCAX : -$2.52
PB Ratio CADL : 5.18 BCAX : 2.73
Total Revenue (TTM) CADL : $0.00 BCAX : $0.00
Gross Profit (TTM) CADL : -$682.00K BCAX : $0.00
EBITDA (TTM) CADL : -$23.05M BCAX : -$151.12M

Returns By Period

In the year-to-date period, CADL achieves a -13.27% return, which is significantly lower than BCAX's 18.18% return.

CADL

• 1D: 9.38%
• 1M: -6.67%
• YTD: -13.27%
• 6M: -3.92%
• 1Y: -13.27%
• 3Y*: 53.68%
• 5Y*: —
• 10Y*: —

BCAX

• 1D: 4.46%
• 1M: 18.53%
• YTD: 18.18%
• 6M: 25.97%
• 1Y: 52.65%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CADL vs. BCAX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CADL

CADL Risk / Return Rank: 31
CADL Sharpe Ratio Rank: 33
CADL Sortino Ratio Rank: 35
CADL Omega Ratio Rank: 34
CADL Calmar Ratio Rank: 27
CADL Martin Ratio Rank: 27

BCAX

BCAX Risk / Return Rank: 64
BCAX Sharpe Ratio Rank: 63
BCAX Sortino Ratio Rank: 63
BCAX Omega Ratio Rank: 66
BCAX Calmar Ratio Rank: 64
BCAX Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CADL vs. BCAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Candel Therapeutics, Inc. (CADL) and Bicara Therapeutics Inc (BCAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CADL	BCAX	Difference
Sharpe ratio Return per unit of total volatility	-0.19	0.64	-0.82
Sortino ratio Return per unit of downside risk	0.23	1.33	-1.10
Omega ratio Gain probability vs. loss probability	1.03	1.19	-0.17
Calmar ratio Return relative to maximum drawdown	-0.47	1.09	-1.57
Martin ratio Return relative to average drawdown	-0.86	2.28	-3.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CADL vs. BCAX - Sharpe Ratio Comparison

The current CADL Sharpe Ratio is -0.19, which is lower than the BCAX Sharpe Ratio of 0.64. The chart below compares the historical Sharpe Ratios of CADL and BCAX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CADL	BCAX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.19	0.64	-0.82
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	-0.13	+0.08

Correlation

The correlation between CADL and BCAX is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CADL vs. BCAX - Dividend Comparison

Neither CADL nor BCAX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CADL vs. BCAX - Drawdown Comparison

The maximum CADL drawdown since its inception was -94.33%, which is greater than BCAX's maximum drawdown of -67.82%. Use the drawdown chart below to compare losses from any high point for CADL and BCAX.

Drawdown Indicators

	CADL	BCAX	Difference
Max Drawdown Largest peak-to-trough decline	-94.33%	-67.82%	-26.51%
Max Drawdown (1Y) Largest decline over 1 year	-37.04%	-44.38%	+7.34%
Current Drawdown Current decline from peak	-65.00%	-26.52%	-38.48%
Average Drawdown Average peak-to-trough decline	-63.27%	-42.47%	-20.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.47%	21.23%	-0.76%

Volatility

CADL vs. BCAX - Volatility Comparison

Candel Therapeutics, Inc. (CADL) has a higher volatility of 18.36% compared to Bicara Therapeutics Inc (BCAX) at 12.58%. This indicates that CADL's price experiences larger fluctuations and is considered to be riskier than BCAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CADL	BCAX	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.36%	12.58%	+5.78%
Volatility (6M) Calculated over the trailing 6-month period	49.60%	44.11%	+5.49%
Volatility (1Y) Calculated over the trailing 1-year period	71.34%	83.30%	-11.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	169.43%	80.18%	+89.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	169.43%	80.18%	+89.25%

Financials